Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
2011 ◽
Vol 29
(15_suppl)
◽
pp. 4591-4591
◽
2016 ◽
Vol 46
(6)
◽
pp. 568-574
◽
2013 ◽
Vol 31
(7)
◽
pp. 1283-1291
◽